Compare FCO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCO | XLO |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | FCO | XLO |
|---|---|---|
| Price | $3.10 | $0.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 100.1K | ★ 480.4K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 14.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $4.73 | $0.53 |
| 52 Week High | $6.63 | $1.70 |
| Indicator | FCO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 27.57 |
| Support Level | $3.11 | $0.53 |
| Resistance Level | $3.26 | $0.63 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.91 | 16.05 |
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.